Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report

The document presents a case study of a 21-year-old female with severe alopecia areata (AA), a common immune-mediated cause of hair loss. The patient had a 15-year history of AA and was treated with baricitinib, a selective JAK1 and JAK2 inhibitor approved in 2022 for severe AA. The patient showed rapid improvement within the first month of treatment, with total hair restoration achieved after two months. The Severity of Alopecia Tool (SALT) score, used to assess the severity of the disease, reduced from 88 to 30 in the first month and to 10 in the second month. Six months later, the patient showed no signs of relapse and continues the same treatment. The authors conclude that baricitinib is a safe, adequate, and fast remedy for AA, with the patient achieving almost total hair restoration within three months of treatment.